CORRESP Filing
Anixa Biosciences Inc
Date: Sept. 26, 2025 · CIK: 0000715446 · Accession: 0001493152-25-015776
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290178
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Chris Edwards Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 10, 2025 File No. 333-290178
Dear Mr. Edwards:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on Tuesday, September 30, 2025, or as soon as thereafter practicable.
Very
truly yours,
/s/
Dr. Amit Kumar
Show Raw Text
CORRESP 1 filename1.htm Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 September 26, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Chris Edwards Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 10, 2025 File No. 333-290178 Dear Mr. Edwards: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on Tuesday, September 30, 2025, or as soon as thereafter practicable. Very truly yours, /s/ Dr. Amit Kumar Dr. Amit Kumar Chairman and Chief Executive Officer cc: Ellenoff Grossman & Schole LLP